CAPN12: A Promising Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: CAPN12

NCBI ID: G147968

CAPN12

CAPN12: A Promising Drug Target and Biomarker for Neurodegenerative Disorders

Introduction

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and their respective neurotransmitters, leading to a range of symptoms and impairments. The underlying causes of these diseases are still not fully understood, but research has identified several potential drug targets and biomarkers that may help elucidate their pathophysiology. One such protein is CAPN12, a calcium-activated neutral proteinase that is expressed in various tissues and cell types, including the brain. In this article, we will explore the potential implications of CAPN12 as a drug target and biomarker for neurodegenerative diseases.

CAPN12: Structure and Function

CAPN12 is a 12-kDa protein that is expressed in a variety of tissues, including the brain, heart, liver, and kidneys. It is localized to the endoplasmic reticulum (ER) and can be internalized by endosomal systems, including the endoplasmic reticulum- associated degradation (ERAD) system. ERAD is a transmembrane protein that is involved in the delivery and degradation of proteins to the ER, and it is thought to play a crucial role in the regulation of intracellular protein levels.

The catalytic active site of CAPN12 is located at its N-terminus and is critical for its proteinase activity. The site consists of a unique catalytic core that is composed of a Rossmann-fold and an imidazole ring. The Rossmann-fold is a structural motif that is commonly found in protein-coding regions and is known for its ability to form a stable complex with various small molecules, including calcium ions. The imidazole ring is an aromatic ring that is formed by the fusion of a imidazole base and a cyclohexane ring.

CAPN12 functions as a neutral proteinase, that is involved in the hydrolysis of a wide variety of proteins, including neurotransmitters and other intracellular molecules. It is activated by the presence of calcium ions and serves as a critical regulator of intracellular protein levels, as well as participating in the regulation of cellular signaling pathways.

CAPN12 as a Drug Target

CAPN12 has been identified as a potential drug target for neurodegenerative diseases due to its unique structure and function. The N-terminus of CAPN12 contains a catalytic core that is sensitive to calcium ions, and it is thought to play a crucial role in the regulation of intracellular protein levels. This is the reason why CAPN12 has been shown to be involved in the regulation of various cellular processes, including the regulation of neurotransmitter release and neurotransmission.

One of the potential strategies to target CAPN12 is to inhibit its catalytic activity by blocking its N-terminus. Alternatively this could be done by using small molecules or antibodies that bind to the N-terminus of CAPN12 and prevent it from forming the catalytic core. , CAPN12 could be targeted by using antibodies that recognize its specific epitope, which is located in the catalytic core.

CAPN12 as a Biomarker

CAPN12 has also been identified as a potential biomarker for neurodegenerative diseases. The levels of CAPN12 have been shown to be affected by a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that CAPN12 may be a useful biomarker for these diseases, as its levels could be affected by the progression of neurodegeneration.

One of the strategies to use CAPN12 as a biomarker is to measure its levels in patient samples, such as brain or urine samples, before and after the onset of the disease. If the levels of CAPN12 are decreased in the patient samples compared to the controls , this could be an indication that the patient has neurodegenerative disease. Additionally, if the levels of CAPN12 are increased in the patient samples compared to the controls, this could be an indication that the patient is at risk for neurodegenerative disease.

Conclusion

CAPN12 is a unique protein that is expressed in various tissues and cell types, including the brain, and has been shown to play a crucial role in the regulation of intracellular protein levels and cellular signaling pathways. Its catalytic activity is regulated by the presence of calcium ions, and it is involved in the hydrolysis of a wide variety of proteins, including neurotransmitters and other intracellular molecules. As a result, CAPN12 has been identified as a potential drug target and biomarker for neurodegenerative diseases. Further research is needed to fully understand its role and potential as a therapeutic tool.

Protein Name: Calpain 12

Functions: Calcium-regulated non-lysosomal thiol-protease

The "CAPN12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CAPN12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets